In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.
A series of novel aromatic derivatives based on the structure of methylglyoxal bis(guanylhydrazone) (MGBG) was examined for trypanocidal activities in human and veterinary trypanosomes of African origin. One agent, CGP 40215A, a bicyclic analog of MGBG which also resembles the diamidines diminazene (Berenil) and pentamidine, was curative of infections by 19 isolates of Trypanosoma brucei subspecies as well as a Trypanosoma congolense isolate. Several of these isolates were resistant to standard trypanocides. Curative doses were < or = 25 mg/kg of body weight/day for 3 days in these acute laboratory model infections. In addition, CGP 40215A also cured a model central nervous system infection in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl, eflornithine). Curative combinations were 14 days of oral 2% DFMO (approximately 5 g/kg/day) plus 5, 10, or 25 mg/kg/day for 3 or 7 days given by intraperitoneal injection or with a miniosmotic pump. Combinations were most effective if CGP 40215A was given in the second half or at the end of the DFMO regimen. MGBG has modest activity as an inhibitor of trypanosome S-adenosylmethionine decarboxylase (50% inhibitory concentration [IC50]. 130 microM), while CGP 40215A was a more active inhibitor (IC50, 20 microM). Preincubation of trypanosomes with CGP 40215A for 1 h caused a reduction in spermidine content (36%) and an increase in putrescine content (20%), indicating that one possible mechanism of its action may be inhibition of polyamine biosynthesis.
Bacchi
C J
CJ
Haskins Laboratories, Pace University, New York, New York 10038, USA.
Brun
R
R
Croft
S L
SL
Alicea
K
K
Bühler
Y
Y
D012437:Adenosylmethionine Decarboxylase / Q000037:antagonists & inhibitors*; D000818:Animals; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D008935:Mitoguazone / Q000031:analogs & derivatives; D011897:Random Allocation; D012370:Robenidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D014344:Trypanocidal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei / Q000187:drug effects* / Q000302:isolation & purification; D016833:Trypanosoma brucei rhodesiense / Q000187:drug effects* / Q000302:isolation & purification; D014348:Trypanosoma congolense / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D014344:Trypanocidal Agents; C102850:bis((3-(aminoiminomethyl)phenyl)methylene)carbonimidic dihydrazide trihydrochloride; D012370:Robenidine; D012437:Adenosylmethionine Decarboxylase; D008935:Mitoguazone